A phase 3, randomized, open-label study of first-line durvalumab (MED14736) +/- tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL
التفاصيل البيبلوغرافية
العنوان:
A phase 3, randomized, open-label study of first-line durvalumab (MED14736) +/- tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL